This disclosure generally relates to therapeutic antibodies for treating Bacillus anthracis (B. anthracis) infection, to specific variants thereof, pharmaceutical composition comprising them and to methods for their use.

Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.

Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.

A method of diagnosing, monitoring progression of, or monitoring treatment of inflammatory bowel disease comprises determining the levels of CD14.sup.+HLA-DR.sup.hi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 in a sample obtained from a subject, wherein high levels of CD14.sup.+HLA-DR.sup.hi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9, or increased levels of CD14.sup.+HLA-DR.sup.hi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 compared to control, indicate the presence or progression of inflammatory bowel disease. Similar methods for diagnosing irritable bowel syndrome are also described. Various companion therapeutic methods and useful binding reagents are also described.

The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.

The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.

The invention relates to a monoclonal antibody against the OprF protein of Pseudomonas aeruginosa or to a functional fragment of this antibody. This antibody or antibody fragment is particularly useful for the preventive or curative treatment of infections with Pseudomonas aeruginosa.

The present invention relates to an antibody having specificity for an immunogenic determinant consisting of the pentasaccharide repeating unit of the Clostridium difficile glycopolymer PS-I: α-L-Rhap-(1.fwdarw.3)-β-D-Glcp-(1.fwdarw.4)-[α-L-Rhap-(1.fwdarw.3)]-α-D-Glcp-(1.fwdarw.2)-α-D-Glcp or a fragment thereof. Said antibody is able to prevent and treat diseases caused by C. difficile. The present invention further pertains to a method of treating or preventing a disease caused by the pathogen Clostridium difficile, which comprises administering to a subject said antibody or a vaccine composition comprising said antibody.

The present invention relates to an antibody having specificity for an immunogenic determinant consisting of the pentasaccharide repeating unit of the Clostridium difficile glycopolymer PS-I: α-L-Rhap-(1.fwdarw.3)-β-D-Glcp-(1.fwdarw.4)-[α-L-Rhap-(1.fwdarw.3)]-α-D-Glcp-(1.fwdarw.2)-α-D-Glcp or a fragment thereof. Said antibody is able to prevent and treat diseases caused by C. difficile. The present invention further pertains to a method of treating or preventing a disease caused by the pathogen Clostridium difficile, which comprises administering to a subject said antibody or a vaccine composition comprising said antibody.

Anaplasma Marginale surface protein OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection.